Personal information

Czech Republic

Activities

Employment (2)

ISCARE I.V.F. a.s.: Praha, CZ

(Inflammatory Bowel Disease Clinical and Research Center)
Employment
Source: Self-asserted source
Martin Kolář

Academy of Sciences of the Czech Republic: Prague, CZ

2013-06-01 to 2014-12-31 (Institute of Biotechnology)
Employment
Source: Self-asserted source
Martin Kolář

Education and qualifications (1)

Charles Univesity: Prague, CZ

(First Faculty of Mecicine)
Education
Source: Self-asserted source
Martin Kolář

Works (28)

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Journal of Immunology Research
2023-06-20 | Journal article
Part of ISSN: 2314-7156
Part of ISSN: 2314-8861
Contributors: Stepan Coufal; Miloslav Kverka; Jakub Kreisinger; Tomas Thon; Filip Rob; Martin Kolar; Zuzana Reiss; Dagmar Schierova; Klara Kostovcikova; Radka Roubalova et al.
Source: Self-asserted source
Martin Kolář

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Frontiers in Cellular and Infection Microbiology
2023-01-10 | Journal article
Part of ISSN: 2235-2988
Contributors: Zuzana Reiss; Filip Rob; Martin Kolar; Dagmar Schierova; Jakub Kreisinger; Zuzana Jackova; Radka Roubalova; Stepan Coufal; Martin Mihula; Tomas Thon et al.
Source: Self-asserted source
Martin Kolář

Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study

PLOS ONE
2022-12-30 | Journal article
Part of ISSN: 1932-6203
Contributors: Filip Rob; Dagmar Schierova; Zuzana Stehlikova; Jakub Kreisinger; Radka Roubalová; Stepan Coufal; Martin Mihula; Zuzana Jackova; Miloslav Kverka; Tomas Thon et al.
Source: Self-asserted source
Martin Kolář

A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts

Scandinavian Journal of Gastroenterology
2022-07-03 | Journal article
Contributors: M. Lukas; M. Kolar; J. Reissigova; D. Duricova; N. Machkova; V. Hruba; M. Lukas; M. Vasatko; J. Jirsa; K. Pudilova et al.
Source: check_circle
Crossref

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Cells
2021-11-16 | Journal article
Part of ISSN: 2073-4409
Contributors: Dagmar Schierova; Radka Roubalova; Martin Kolar; Stehlikova; Filip Rob; Zuzana Jackova; Stepan Coufal; Tomas Thon; Martin Mihula; Martin Modrák et al.
Source: Self-asserted source
Martin Kolář

Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques

Gastrointestinal Endoscopy
2021-01 | Journal article
Contributors: Martin Lukas; Martin Kolar; Ondrej Ryska; Stefan Juhas; Jana Juhasova; Jaroslav Kalvach; Jaroslav Pazin; Tereza Kocisova; Ondrej Foltan; Hana Kristianova et al.
Source: check_circle
Crossref

Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre

Journal of Crohn's and Colitis
2020-07-30 | Journal article
Contributors: Martin Lukas; K Malickova; M Kolar; M Bortlik; M Vasatko; N Machkova; V Hruba; D Duricova; Milan Lukas
Source: check_circle
Crossref

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases

Intestinal Research
2020-01-30 | Journal article
Contributors: Sang Hyoung Park; Jae Cheol Park; Milan Lukas; Martin Kolar; Edward V. Loftus
Source: check_circle
Crossref

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

Gastroenterologie a hepatologie
2019-02-28 | Journal article
Contributors: Karolína Pudilová; Martin Kolář; Dana Ďuricová; Karin Malíčková; Veronika Hrubá; Naděžda Machková; Radka Vaníčková; Karatína Mitrová; Martin Lukáš; Martin Vašátko et al.
Source: check_circle
Crossref

Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice

Gastroenterologie a hepatologie
2019-02-28 | Journal article
Contributors: Martin Kolář; Dana Ďuricová; Martin Bortlík; Karolína Pudilová; Veronika Hrubá; Naděžda Machková; Katarína Mitrová; Karin Malíčková; Martin Lukáš; Martin Vašátko et al.
Source: check_circle
Crossref

Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab

Gastroenterologie a Hepatologie
2018 | Journal article
EID:

2-s2.0-85042529259

Contributors: Kolar, M.; Bortlik, M.; Duricova, D.; Lukas, M.; Hruba, V.; Machkova, N.; Malickova, K.; Lukas, M.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort

Expert Opinion on Biological Therapy
2018-11-02 | Journal article
Contributors: Anita Bálint; Mariann Rutka; Martin Kolar; Martin Bortlik; Dana Duricova; Veronika Hruba; Martin Lukas; Katarina Mitrova; Karin Malickova; Milan Lukas et al.
Source: check_circle
Crossref

Fecal zonulin is elevated in Crohn's disease and in cigarette smokers

Practical Laboratory Medicine
2017 | Journal article
EID:

2-s2.0-85030089146

Contributors: Malíčková, K.; Francová, I.; Lukáš, M.; Kolář, M.; Králíková, E.; Bortlík, M.; Ďuricová, D.; Štěpánková, L.; Zvolská, K.; Pánková, A. et al.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

Expert Opinion on Drug Safety
2017 | Journal article
EID:

2-s2.0-85019756405

Contributors: Bálint, A.; Rutka, M.; Végh, Z.; Kürti, Z.; Gecse, K.B.; Banai, J.; Bene, L.; Gasztonyi, B.; Kristóf, T.; Lakatos, L. et al.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

Dig Dis
2017 | Journal article
Contributors: Kolar, M.; Duricova, D.; Bortlik, M.; Hruba, V.; Machkova, N.; Mitrova, K.; Malickova, K.; Lukas, M.
Source: Self-asserted source
Martin Kolář via ResearcherID

P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients - one-year clinical follow-up

J Crohns Colitis
2017 | Journal article
Contributors: Kolar, M.; Duricova, D.; Bortlik, M.; Hruba, V.; Machkova, N.; Mitrova, K.; Lukas, M.; Malickova, K.
Source: Self-asserted source
Martin Kolář via ResearcherID

11<sup>th</sup> Congress of ECCO, Amsterdam, The Netherlands | 11. kongres ECCO, Amsterdam, Nizozemsko

Gastroenterologie a Hepatologie
2016 | Journal article
EID:

2-s2.0-84968846627

Contributors: Mitrová, K.; Kolář, M.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

Biosimilar infliximab in anti-TNF-naïve IBD patients - 1-year clinical follow-up

Gastroenterologie a Hepatologie
2016 | Journal article
EID:

2-s2.0-85012863835

Contributors: Kolar, M.; Duricova, D.; Bortlik, M.; Hruba, V.; Machkova, N.; Mitrova, K.; Malickova, K.; Lukas, M.; Lukas, M.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naive to anti-TNF therapy: a tertiary centre experience

Journal of Crohns &amp; Colitis
2016 | Journal article
WOSUID:

WOS:000374496600616

Contributors: Bortlik, M.; Kolar, M.; Duricova, D.; Malickova, K.; Hruba, V.; Machkova, N.; Mitrova, K.; Lukas, M.
Source: Self-asserted source
Martin Kolář via ResearcherID

Budesonide MMX (Cortiment® 9 mg) in the treatment of ulcerative colitis in real clinical practice | Budesonid MMX (Cortiment® 9 mg) v léčbě ulcerózní kolitidy v reálné klinické praxi

Gastroenterologie a Hepatologie
2016 | Journal article
EID:

2-s2.0-85012881070

Contributors: Hrdlička, L.; Bortlík, M.; Douda, T.; Drastich, P.; Falt, P.; Matějkové, P.; Koželuhová, J.; Liberda, M.; Nedbalová, L.; Novotný, A. et al.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation

Scandinavian Journal of Gastroenterology
2016 | Journal article
WOSUID:

WOS:000373776500009

Contributors: Bortlik, Martin; Duricova, Dana; Machkova, Nadezda; Hruba, Veronika; Lukas, Martin; Mitrova, Katarina; Romanko, Igor; Bina, Vladislav; Malickova, Karin; Kolar, Martin et al.
Source: Self-asserted source
Martin Kolář via ResearcherID

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

Journal of Crohns &amp; Colitis
2016 | Journal article
WOSUID:

WOS:000387990000004

Contributors: Farkas, Klaudia; Rutka, Mariann; Golovics, Petra A.; Vegh, Zsuzsanna; Lovasz, Barbara D.; Nyari, Tibor; Gecse, Krisztina B.; Kolar, Martin; Bortlik, Martin; Duricova, Dana et al.
Source: Self-asserted source
Martin Kolář via ResearcherID

Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis: data from 2 Central European countries

Journal of Crohns &amp; Colitis
2016 | Journal article
WOSUID:

WOS:000374496600062

Contributors: Farkas, K.; Rutka, M.; Golovics, P. A.; Vegh, Z.; Lovasz, B. D.; Nyari, T.; Gecse, K. B.; Kolar, M.; Bortlik, M.; Duricova, D. et al.
Source: Self-asserted source
Martin Kolář via ResearcherID

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from a Central European nationwide cohort

Journal of Crohns &amp; Colitis
2016 | Journal article
WOSUID:

WOS:000374496600041

Contributors: Balint, A.; Farkas, K.; Rutka, M.; Vegh, Z.; Kurti, Z.; Banai, J.; Bene, L.; Gasztonyi, B.; Kristof, T.; Lakatos, L. et al.
Source: Self-asserted source
Martin Kolář via ResearcherID

Guidelines for the administration of bio logical therapy in patients with infl ammatory bowel diseases: Third, updated edition | Doporučení pro podávání bio logické terapie u idiopatických střevních zánětů: Třetí, aktualizované vydání

Gastroenterologie a Hepatologie
2016 | Journal article
EID:

2-s2.0-84960843984

Contributors: Bortlík, M.; Ďuricová, D.; Kohout, P.; Konečný, M.; Koželuhová, J.; Novotný, A.; Zbořil, V.; Prokopová, L.; Douda, T.; Stehlík, J. et al.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

Long-term functional outcomes and quality of life after restorative proctocolectomy and ileal pouch-anal anastomosis | Dlouhodobé funkční výsledky a kvalita života nemocných s ulcerózní kolitidou po proktokolektomii s ileopouch-anální anastomózou

Gastroenterologie a Hepatologie
2016 | Journal article
EID:

2-s2.0-84960877481

Contributors: Kostrejová, M.; Bortlik, M.; Ďuricová, D.; Kolář, M.; Sequens, R.; Lukáš, M.
Source: Self-asserted source
Martin Kolář via Scopus - Elsevier

No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results

Journal of Crohns &amp; Colitis
2016 | Journal article
WOSUID:

WOS:000374496600432

Contributors: Malickova, K.; Duricova, D.; Kolar, M.; Bortlik, M.; Hruba, V.; Machkova, N.; Mitrova, K.; Lukas, M., Jr.; Lukas, M.
Source: Self-asserted source
Martin Kolář via ResearcherID

Switching of patients with inflammatory bowel disease from original infliximab (Remicade (R)) to biosimilar infliximab (Remsima (TM)) is effective and safe

Journal of Crohns &amp; Colitis
2016 | Journal article
WOSUID:

WOS:000374496600063

Contributors: Kolar, M.; Duricova, D.; Brotlik, M.; Hruba, V.; Machkova, N.; Mitrova, K.; Malickova, K.; Lukas, M.
Source: Self-asserted source
Martin Kolář via ResearcherID